Natural or deliberate exposure to smallpox poses a great health threat, especially since routine smallpox vaccinations have been discontinued and no clinically approved treatment currently exists. In the February 1 issue of the Journal of Clinical Investigation, Ellis Reinherz and colleagues from Harvard Medical School propose a new antiviral therapy – a low molecular weight inhibitor of signaling mediated by the smallpox growth factor (SPGF).
